MX2016014740A - Un metodo para el tratamiento de trastornos del movimiento con befiradol. - Google Patents

Un metodo para el tratamiento de trastornos del movimiento con befiradol.

Info

Publication number
MX2016014740A
MX2016014740A MX2016014740A MX2016014740A MX2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A MX 2016014740 A MX2016014740 A MX 2016014740A
Authority
MX
Mexico
Prior art keywords
befiradol
treatment
movement disorders
administration
patient
Prior art date
Application number
MX2016014740A
Other languages
English (en)
Other versions
MX374938B (es
Inventor
Varney Mark
Paillard Bruno
DEL FRARI Laurence
BRUNNER Valérie
Newman Tancredi Adrian
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2016014740A publication Critical patent/MX2016014740A/es
Publication of MX374938B publication Critical patent/MX374938B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de trastornos del movimiento comprendiendo la administración, a un paciente en la necesidad de ello, de una cantidad eficaz de befiradol, donde en el paso de la administración se le proporciona a un paciente una concentración máxima de befiradol en plasma por debajo de los 15 ng/ml, misma que se obtiene después de más de 4 horas posteriores a la administración, dicho método minimizando los efectos secundarios del mareo y la náusea. También se describen composiciones farmacéuticas de liberación sostenida que pueden ser utilizadas de acuerdo con este método.
MX2016014740A 2014-07-09 2015-07-09 Un método para el tratamiento de trastornos del movimiento con befiradol. MX374938B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022462P 2014-07-09 2014-07-09
PCT/EP2015/065763 WO2016005527A1 (en) 2014-07-09 2015-07-09 A method for treating movement disorders with befiradol

Publications (2)

Publication Number Publication Date
MX2016014740A true MX2016014740A (es) 2017-03-06
MX374938B MX374938B (es) 2025-03-06

Family

ID=53682662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014740A MX374938B (es) 2014-07-09 2015-07-09 Un método para el tratamiento de trastornos del movimiento con befiradol.

Country Status (16)

Country Link
US (3) US10548885B2 (es)
EP (1) EP3131549B1 (es)
JP (2) JP6636458B2 (es)
KR (1) KR102533428B1 (es)
CN (1) CN106456622B (es)
AU (1) AU2015286675B2 (es)
CA (1) CA2946829C (es)
DK (1) DK3131549T3 (es)
ES (1) ES2668379T3 (es)
HU (1) HUE037945T2 (es)
MX (1) MX374938B (es)
PL (1) PL3131549T3 (es)
PT (1) PT3131549T (es)
RU (1) RU2702101C2 (es)
WO (1) WO2016005527A1 (es)
ZA (1) ZA201607419B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015286675B2 (en) * 2014-07-09 2017-08-24 Pierre Fabre Medicament A method for treating movement disorders with befiradol
WO2017205387A1 (en) * 2016-05-23 2017-11-30 Northwestern University Systems and methods for untargeted metabolomic screening
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
US11191758B2 (en) 2017-07-20 2021-12-07 Neurolixis Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
AU2024238367A1 (en) 2023-03-19 2025-10-09 Neurolixis, Inc. Method for treating l-dopa-induced dyskinesia using befiradol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
US6060345A (en) * 1997-04-21 2000-05-09 Advanced Micro Devices, Inc. Method of making NMOS and PMOS devices with reduced masking steps
FR2820743B1 (fr) 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
KR101231856B1 (ko) * 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
US7040843B1 (en) 2005-03-17 2006-05-09 Great Lakes Custom Tool Mfg., Inc. Flooring hollow back relief cutting tool and method
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
WO2011008546A2 (en) * 2009-06-29 2011-01-20 Capricorn Pharma, Inc. Solid and semi-solid dosage forms and systems and methods for forming and packaging thereof
WO2011099573A1 (ja) * 2010-02-12 2011-08-18 大正製薬株式会社 徐放性製剤
AU2011232408B2 (en) * 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
WO2012030314A1 (en) 2010-09-01 2012-03-08 Mithridion, Inc. Compositions comprising 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine, and methods of administering same
CA2813648C (en) * 2010-10-15 2019-06-25 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
EP2729176A1 (en) * 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
SG11201406690SA (en) * 2012-04-18 2014-11-27 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US9555993B2 (en) 2012-04-18 2017-01-31 Jesco Holding A/S Winding apparatus for winding a web into a roll
AU2015286675B2 (en) * 2014-07-09 2017-08-24 Pierre Fabre Medicament A method for treating movement disorders with befiradol
WO2025035048A1 (en) 2023-08-09 2025-02-13 Via Separations, Inc. Filtration apparatus comprising polymer modified graphene oxide membranes

Also Published As

Publication number Publication date
CN106456622A (zh) 2017-02-22
HUE037945T2 (hu) 2018-09-28
WO2016005527A1 (en) 2016-01-14
EP3131549B1 (en) 2018-03-28
CA2946829A1 (en) 2016-01-14
US20210338646A1 (en) 2021-11-04
KR20170029407A (ko) 2017-03-15
AU2015286675B2 (en) 2017-08-24
DK3131549T3 (en) 2018-05-28
US20200138800A1 (en) 2020-05-07
EP3131549A1 (en) 2017-02-22
US10548885B2 (en) 2020-02-04
JP2017524651A (ja) 2017-08-31
MX374938B (es) 2025-03-06
BR112016026648A2 (pt) 2017-08-15
US12472169B2 (en) 2025-11-18
CA2946829C (en) 2018-05-22
JP2018138568A (ja) 2018-09-06
ZA201607419B (en) 2023-12-20
RU2016143875A (ru) 2018-08-10
JP6824924B2 (ja) 2021-02-03
CN106456622B (zh) 2020-05-19
AU2015286675A1 (en) 2016-11-24
ES2668379T3 (es) 2018-05-17
US11090298B2 (en) 2021-08-17
US20170239231A1 (en) 2017-08-24
JP6636458B2 (ja) 2020-01-29
RU2016143875A3 (es) 2019-02-01
PL3131549T3 (pl) 2018-09-28
PT3131549T (pt) 2018-07-04
BR112016026648A8 (pt) 2021-07-20
RU2702101C2 (ru) 2019-10-04
KR102533428B1 (ko) 2023-05-16

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
NI201800040A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CO2018009559A2 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CO2017002309A1 (es) Composiciones farmacéuticas útiles en el tratamiento de la insuficiencia cardiaca congestiva

Legal Events

Date Code Title Description
FG Grant or registration